γμβ μϊελο δςξεγ

ρψβμ πβιωεϊ

 

|
ξϊλεπιν (6,394)
|
αλμ δΰϊψ

ψαμιξιγ 10 ξ"β

ων δϊψετδ αΰπβμιϊ: Revlimid ® 10 Mg. ξητωιν ϊψετδ ΰηψϊ? λπρε μΰιπγχρ δϊψετεϊ »
αρμ δαψιΰεϊ αρμ δαψιΰεϊ
|
ωϊσ α-

φεψϊ ξϊο

PER OS

ξιπεο

Capsules

ωιξεω αϊψετδ

REVLIMID is indicated for 1. Treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. In combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.3. Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib

ξρτψ ψιωεν

140 46 31661 16

ιφψο

Celgene Europe Ltd, Uk

ϊεχσ ψιωιεο μϊψετδ

07/2014 - 04/2024

δϊλπιν δξετιςιν αΰϊψ ζδ πεςγε μρτχ ΰιπτεψξφιδ λμμιϊ αμαγ.
ΰιπν ξδεειν δξμφδ, ϊημισ μδϊιιςφεϊ ςν ξεξηδ ΰε χαμϊ ιιςευ ψτεΰι.
αωιξεω ΰε φτιιδ απϊεπιν ωαΰϊψ διπκ ξΰωψ ΰϊ ϊπΰι δωιξεω αΰϊψ.
ηεξψ τςιμ ψιλεζ / λξεϊ αιηιγϊ ξιπεο
Lenalidomide 10 MG
ΰψιζδ λξεϊ αΰψιζδ ηιι ξγσ ϊψετϊ ξψων
Blister pvc/pctfe 21 x CAPSULES 36 ηεγωιν λο

*

*

χιωεψιν ιδτλε αΰετο ΰεθεξθι μμηιφιν
 

αωμιηϊ ϊβεαδ ΰπι ξχαμ ΰϊ ϊπΰι δωιξεω αΰϊψ.

 
δψων μΰϊψ εχαμ ςγλεπιν ιωιψεϊ μγεΰ"μ ωμκ!
 

ξηωαεο δψιεο

λμ δτψθιν ςμ δδψιεο ωμκ. λπρι: μξηωαεο δψιεο »
345 χμεψιεϊ
ςεβϊ βαιπδ θαςεπιϊ ςν τιψεϊ ιςψ
ςεβϊ βαιπδ θαςεπιϊ ξεωμξϊ ξαφχ ωμ ΰβεζι ξμκ, ωχγιν εϊξψιν, εαξιμει ωμ χψν ΰβεζι χωιε μιξεπι ξτπχ εξηιϊ ΰελξπιεϊ ΰε λμ τψι ιςψ ΰηψ ωΰεδαιν